What You Should Know:
– Johns Hopkins University has signed an agreement with Rose Hill Life Sciences, a global leader in the research and intellectual property of premium psilocybin products to exclusively license intellectual property related to improving motor functions in patients with neurological injuries through the use of psychedelic therapy.
– The collaboration aims to explore the potential of psilocybin to enhance recovery from conditions such as stroke.
Transforming Stroke Recovery Through Psilocybin-Enhanced Neuroplasticity
This Phase 1 trial investigates whether combining psilocybin with digitally enhanced physical therapy can reignite neuroplasticity and reopen recovery windows long after a stroke — a potential paradigm shift in how we treat long-term disability. The trial is led by renowned researchers Drs. Gül Dölen, Steve Zeiler, and John Krakauer at Johns Hopkins.
The licensed invention encompasses methods for improving motor function in individuals who have experienced an acute, subacute, or chronic central nervous system (CNS) injury, as well as for treating focal diaschisis (a sudden loss of function in a portion of the brain connected to a distant, damaged brain area) caused by such injuries. Experts involved in the development of this intellectual property believe that psilocybin-assisted therapy could offer a new paradigm for neurological rehabilitation, particularly for stroke survivors.
Gül Dölen, MD, PhD, Professor and Parson’s Endowed Chair of Neuroscience and Psychology at UC Berkeley and Adjunct Professor of Neuroscience and Neurology at Johns Hopkins University, added, “Psychedelics have shown remarkable potential to reopen critical periods — if harnessed correctly this reopened window of brain malleability, could revolutionize stroke rehabilitation. This license represents an exciting step toward understanding how psilocybin can rewire the brain, potentially leading to more effective and lasting recovery strategies for stroke survivors”.
Rose Hill’s Commitment to Advancing Psychedelic Medicine
Rose Hill Life Sciences, known as the world’s inaugural legal exporter of psilocybin, is dedicated to advancing scientific research and expanding the therapeutic applications of psilocybin. The company supports pioneering clinical research exploring psilocybin’s potential for treating mental health and neurological conditions through its integrated operations spanning Jamaica, the United States, and Canada, and via strategic partnerships with esteemed research institutions.
